| abstract |
Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo [2.2.2] oct-1-yl]-4-methyl-5 -(2-trifluoromethyl-phenyl) -4H-1,2,4-triazole are potent inhibitors of 110-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment. |